Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2017 Oct 24;10(10):CD001146.
doi: 10.1002/14651858.CD001146.pub5.

Early (< 8 days) systemic postnatal corticosteroids for prevention of bronchopulmonary dysplasia in preterm infants

Lex W Doyle  1 , Jeanie L Cheong, Richard A Ehrenkranz, Henry L Halliday
Affiliations
Meta-Analysis

Early (< 8 days) systemic postnatal corticosteroids for prevention of bronchopulmonary dysplasia in preterm infants

Lex W Doyle et al. Cochrane Database Syst Rev. .

Update in

Abstract

Background: Bronchopulmonary dysplasia remains a major problem in neonatal intensive care units. Persistent inflammation in the lungs is the most likely underlying pathogenesis. Corticosteroids have been used to prevent or treat bronchopulmonary dysplasia because of their potent anti-inflammatory effects.

Objectives: To examine the relative benefits and adverse effects of systemic postnatal corticosteroids commenced within the first seven days of life for preterm infants at risk of developing bronchopulmonary dysplasia.

Search methods: For the 2017 update, we used the standard search strategy of Cochrane Neonatal to search the Cochrane Central Register of Controlled Trials (CENTRAL; 2017, Issue 1); MEDLINE via PubMed (January 2013 to 21 February 2017); Embase (January 2013 to 21 February 2017); and the Cumulative Index to Nursing and Allied Health Literature (CINAHL) (January 2013 to 21 February 2017). We also searched clinical trials databases, conference proceedings, and reference lists of retrieved articles for randomised controlled trials (RCTs) and quasi-randomised trials.

Selection criteria: For this review, we selected RCTs examining systemic postnatal corticosteroid treatment within the first seven days of life (early) in high-risk preterm infants. Most studies evaluated the use of dexamethasone, but we also included studies that assessed hydrocortisone, even when used primarily for management of hypotension.

Data collection and analysis: We used the GRADE approach to assess the quality of evidence.We extracted and analysed data regarding clinical outcomes that included mortality, bronchopulmonary dysplasia, death or bronchopulmonary dysplasia, failure to extubate, complications during primary hospitalisation, and long-term health outcomes.

Main results: We included 32 RCTs enrolling a total of 4395 participants. The overall risk of bias of included studies was probably low, as all were RCTs, and most trials used rigorous methods. Investigators reported significant benefits for the following outcomes overall: lower rates of failure to extubate, decreased risks of bronchopulmonary dysplasia both at 28 days of life and at 36 weeks' postmenstrual age, death or bronchopulmonary dysplasia at 28 days of life and at 36 weeks' postmenstrual age, patent ductus arteriosus, and retinopathy of prematurity (ROP), including severe ROP. Researchers found no significant differences in rates of neonatal or subsequent mortality; they noted that gastrointestinal bleeding and intestinal perforation were important adverse effects, and that risks of hyperglycaemia, hypertension, hypertrophic cardiomyopathy, and growth failure were increased. The 13 trials that reported late outcomes described several adverse neurological effects at follow-up examination, including cerebral palsy. However, study authors indicated that major neurosensory disability was not significantly increased, either overall in the eight studies for which this outcome could be determined, or in the two individual studies in which rates of cerebral palsy or abnormal neurological examination were significantly increased. Moreover, data show that rates of the combined outcomes of death or cerebral palsy, or of death or major neurosensory disability, were not significantly increased. Two-thirds of studies used dexamethasone (n = 21). Subgroup analyses by type of corticosteroid revealed that most of the beneficial and harmful effects of treatment were attributable to dexamethasone. However, as with dexamethasone, hydrocortisone was associated with reduced rates of patent ductus arteriosus, mortality, and the combined outcome of mortality or chronic lung disease, but with increased occurrence of intestinal perforation. Results showed that hydrocortisone was not associated with obvious longer-term problems.Use of the GRADE approach revealed that the quality of evidence was high for the major outcomes considered, but review authors downgraded quality one level for several outcomes (mortality at latest age, bronchopulmonary dysplasia at 36 weeks, and death or bronchopulmonary dysplasia at 36 weeks) because of weak evidence of publication bias or moderate heterogeneity (death or cerebral palsy).

Authors' conclusions: Benefits of early postnatal corticosteroid treatment (≤ 7 days), particularly dexamethasone, may not outweigh adverse effects associated with this treatment. Although early corticosteroid treatment facilitates extubation and reduces risk of bronchopulmonary dysplasia and patent ductus arteriosus, it causes short-term adverse effects including gastrointestinal bleeding, intestinal perforation, hyperglycaemia, hypertension, hypertrophic cardiomyopathy, and growth failure. Long-term follow-up studies report increased risk of abnormal findings on neurological examination and increased risk of cerebral palsy. However, the methodological quality of studies examining long-term outcomes is limited in some cases: Surviving children have been assessed predominantly before school age; no study has been sufficiently powered to detect important adverse long-term neurosensory outcomes; and no study has been designed with survival free of adverse long-term neurodevelopmental disability as the primary outcome. There is a compelling need for long-term follow-up and reporting of late outcomes, especially neurological and developmental outcomes, among surviving infants who participated in all randomised trials of early postnatal corticosteroid treatment. Hydrocortisone reduced rates of patent ductus arteriosus, of mortality, and of the combined outcome of mortality or bronchopulmonary dysplasia, without causing any obvious long-term harm. However, gastrointestinal perforation was more frequent in the hydrocortisone group. Longer-term follow-up into late childhood is vital for assessment of important effects or other effects that cannot be assessed in early childhood, such as effects of early hydrocortisone treatment on higher-order neurological functions, including cognitive function, academic performance, behaviour, mental health, and motor function. Further randomised controlled trials of early hydrocortisone should include longer-term survival free of neurodevelopmental disability as the main outcome.

PubMed Disclaimer

Conflict of interest statement

Lex Doyle was Chief Investigator in the DART study, a randomised controlled trial of low‐dose, short‐course dexamethasone in ventilator‐dependent infants that was funded by the National Health and Medical Research Council of Australia.

Henry Halliday (HLH) is a retired neonatologist. He is joint Editor‐in‐Chief of the journal Neonatology and sits on many Data Monitoring and Trial Steering Committees for various neonatal/perinatal trials. He has received support in the past for co‐ordinating the OSECT study (2000), for which AstraZeneca (Sweden) supplied metered‐dose inhalers of budesonide and placebo. HLH also acts as a consultant for Chiesi Farmiceutici (Italy), a company that sells two neonatal drugs ‐ Curosurf (a surfactant to treat respiratory distress syndrome) and Peyona (a caffeine preparation to treat apnoea of prematurity).

Figures

1
1
Study flow diagram: review update.
2
2
Funnel plot of comparison: 1 Mortality, outcome: 1.4 Mortality at latest reported age.
3
3
Funnel plot of comparison: 2 Bronchopulmonary dysplasia (BPD), outcome: 2.2 BPD (36 weeks' postmenstrual age).
4
4
Funnel plot of comparison: 3 Death or bronchopulmonary dysplasia (BPD), outcome: 3.2 Death or BPD at 36 weeks' postmenstrual age.
5
5
Funnel plot of comparison: 6 Long‐term follow‐up, outcome: 6.11 Cerebral palsy.
See this image and copyright information in PMC

Update of

References

References to studies included in this review

Anttila 2005 {published data only}
    1. Anttila E, Peltonemi O, Haumont D, Herting E, ter Horst H, Heinonen K, et al. Early neonatal dexamethasone treatment for prevention of bronchopulmonary dysplasia. Randomised trial and meta‐analysis evaluating the duration of dexamethasone therapy. European Journal of Pediatrics 2005;164(8):472‐81. [DOI: 10.1007/s00431-005-1645-8; PUBMED: 15864643] - DOI - PubMed
Baden 1972 {published data only}
    1. Baden M, Bauer CR, Cole E, Klein G, Taeusch HW, Stern L. A controlled trial of hydrocortisone therapy in infants with respiratory distress syndrome. Pediatrics 1972;50(4):526‐34. [PUBMED: 4561296] - PubMed
    1. Fitzhardinge PM, Eisen A, Lejtenyi C, Metrakos K, Ramsay M. Sequelae of early steroid administration to the newborn infant. Pediatrics 1974;53(6):877‐83. [PUBMED: 4598934] - PubMed
Batton 2012 {published data only}
    1. Batton BJ, Li L, Newman NS, Das A, Watterberg KL, Yoder BA, et al. Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network. Feasibility study of early blood pressure management in extremely preterm infants. Journal of Pediatrics 2012;161(1):65‐9. [DOI: 10.1016/j.jpeds.2012.01.014; PUBMED: 22336574] - DOI - PMC - PubMed
Baud 2016 {published data only}
    1. Baud O, Maury L, Lebail F, Ramful D, Moussawi F, Nicaise C, et al. PREMILOC Trial Study Group. Effect of early low‐dose hydrocortisone on survival without bronchopulmonary dysplasia in extremely preterm infants (PREMILOC): a double‐blind, placebo‐controlled, multicentre, randomised trial. Lancet 2016;387(10030):1827‐36. [DOI: 10.1016/S0140-6736(16)00202-6; PUBMED: 26916176] - DOI - PubMed
    1. Baud O, Trousson C, Biran V, Leroy E, Mohamed D, Alberti C, PREMILOC Trial Group. Association between early low‐dose hydrocortisone therapy in extremely preterm neonates and neurodevelopmental outcomes at 2 years of age. JAMA 2017;317(13):1329‐37. [DOI: 10.1001/jama.2017.2692; PUBMED: 28384828] - DOI - PubMed
Biswas 2003 {published data only}
    1. Biswas S. Personal communication. email 2002.
    1. Biswas S, Buffery J, Enoch H, Bland M, Markiewicz M, Walters D. Pulmonary effects of triiodothyronine (T3) and hydrocortisone (HC) supplementation in preterm infants less than 30 weeks gestation: results of the THORN trial ‐ thyroid hormone replacement in neonates. Pediatric Research 2003;53(1):48‐56. [DOI: 10.1203/00006450-200301000-00011; PUBMED: 12508081] - DOI - PubMed
Bonsante 2007 {published data only}
    1. Bonsante F, Latorre G, Lacobelli S, Forziati V, Laforgia N, Esposito L, et al. Early low‐dose hydrocortisone in very preterm infants: a randomized placebo‐controlled trial. Neonatology 2007;91(4):217‐21. [DOI: 10.1159/000098168; PUBMED: 17568152] - DOI - PubMed
Efird 2005 {published data only}
    1. Efird MM, Heerens AT, Gordon PV, Bose CL, Young DA. A randomized‐controlled trial of prophylactic hydrocortisone supplementation for the prevention of hypotension in extremely low birth weight infants. Journal of Perinatology 2005;25(2):119‐24. [DOI: 10.1038/sj.jp.7211193; PUBMED: 15329742] - DOI - PubMed
Garland 1999 {published data only}
    1. Garland JS, Alex CP, Pauly TH, Whitehead VL, Brand J, Winston JF, et al. A three‐day course of dexamethasone therapy to prevent chronic lung disease in ventilated neonates: a randomized trial. Pediatrics 1999;104(1 Pt 1):91‐9. [PUBMED: 10390266] - PubMed
Halac 1990 {published data only}
    1. Halac E, Halac J, Begue EF, Casañas JM, Indiveri DR, Petit JF, et al. Prenatal and postnatal corticosteroid therapy to prevent neonatal necrotizing enterocolitis: a controlled trial. Journal of Pediatrics 1990;117(1 Pt 1):132‐8. [PUBMED: 2196355] - PubMed
Hochwald 2014 {published data only}
    1. Hochwald O, Palegra G, Osiovich O. Adding hydrocortisone as 1st line of inotropic treatment for hypotension in very low birth weight infants. Indian Journal of Pediatrics 2014;81(8):808‐10. [DOI: 10.1007/s12098-013-1151-3; PUBMED: 23904065] - DOI - PubMed
Kopelman 1999 {published data only}
    1. Kopelman AE, Moise AA, Holbert D, Hegemier SE. A single very early dexamethasone dose improves respiratory and cardiovascular adaptation in preterm infants. Journal of Pediatrics 1999;135(3):345‐50. [PUBMED: 10484801] - PubMed
Lauterbach 2006 {published data only}
    1. Lauterbach R, Szymura‐Oleksiak J, Pawlik D, Warchol J, Lisowska‐Miszczyk I, Rytlewski K. Nebulized pentoxifylline for prevention of bronchopulmonary dysplasia in very low birth weight infants: a pilot clinical study. Journal of Maternal‐Fetal & Neonatal Medicine 2006;19(7):433‐8. [DOI: 10.1080/14767050600736754; PUBMED: 16923699] - DOI - PubMed
Lin 1999 {published data only}
    1. Lin YJ, Yeh TF, Hsieh WS, Chi YC, Lin HC, Lin CH. Prevention of chronic lung disease in preterm infants by early postnatal dexamethasone therapy. Pediatric Pulmonology 1999;27(1):21‐6. [PUBMED: 10023787] - PubMed
Mukhopadhyay 1998 {published data only}
    1. Mukhopadhyay K, Kumar P, Narang A. Role of early postnatal dexamethasone in respiratory distress syndrome. Indian Pediatrics 1998;35(2):117‐22. [PUBMED: 9707853] - PubMed
Ng 2006 {published data only}
    1. Ng PC, Lee CH, Bnur FL, Chan IH, Lee AW, Wong E, et al. A double‐blind randomized controlled study of a stress dose of hydrocortisone for rescue treatment of refractory hypotension in preterm infants. Pediatrics 2006;117(2):367‐75. [DOI: 10.1542/peds.2005-0869; PUBMED: 16452355] - DOI - PubMed
Peltoniemi 2005 {published data only}
    1. Peltoniemi O, Kari A, Heinonen K, Saarela T, Nikolajev K, Andersson S, et al. Pretreatment cortisol values may predict responses to hydrocortisone administration for the prevention of bronchopulmonary dysplasia in high‐risk infants. Journal of Pediatrics 2005;146(5):632‐7. [DOI: 10.1016/j.jpeds.2004.12.040; PUBMED: 15870666] - DOI - PubMed
    1. Peltoniemi OM, Lano A, Puosi R, Yliherva A, Bonsante F, Kari MA, et al. Neonatal Hydrocortisone Working Group. Trial of early neonatal hydrocortisone: two‐year follow‐up. Neonatology 2009;95(3):240‐7. [DOI: 10.1159/000164150; PUBMED: 18931525] - DOI - PubMed
    1. Peltoniemi OM, Lano A, Yliherva A, Kari MA, Hallman M, Neonatal Hydrocortisone Working Group. Randomised trial of early neonatal hydrocortisone demonstrates potential undesired effects on neurodevelopment at preschool age. Acta Paediatrica 2016;105(2):159‐64. [DOI: 10.1111/apa.13074; PUBMED: 26058477] - DOI - PubMed
Rastogi 1996 {published data only}
    1. Morales P, Rastogi A, Bez ML, Akintorin SM, Pyati S, Andes SM, et al. Effect of dexamethasone therapy on the neonatal ductus arteriosus. Pediatric Cardiology 1998;19(3):225‐9. [DOI: 10.1007/s002469900290; PUBMED: 9568218] - DOI - PubMed
    1. Rastogi A, Akintorin SM, Bez ML, Morales P, Pildes PS. A controlled trial of dexamethasone to prevent bronchopulmonary dysplasia in surfactant‐treated infants. Pediatrics 1996;98(2 Pt 1):204‐10. [PUBMED: 8692619] - PubMed
Romagnoli 1999 {published data only}
    1. Romagnoli C, Zecca E, Luciano R, Torrioli G, Tortorolo G. Controlled trial of early dexamethasone treatment for the prevention of chronic lung disease in preterm infants: a 3‐year follow‐up. Pediatrics 2002;109(6):e85. [PUBMED: 12042579] - PubMed
    1. Romagnoli C, Zecca E, Vento G, Carolis MP, Papacci P, Tortorolo G. Early postnatal dexamethasone for the prevention of chronic lung disease in high‐risk preterm infants. Intensive Care Medicine 1999;25(7):717‐21. [PUBMED: 10470576] - PubMed
    1. Romagnoli C, Zecca E, Vento G, Maggio L, Papacci P, Tortorolo G. Effect on growth of two different dexamethasone courses for preterm infants at risk of chronic lung disease. A randomized controlled trial. Pharmacology 1999;59(5):266‐74. [DOI: ; PUBMED: 10529659] - PubMed
Sanders 1994 {published data only}
    1. Sanders RJ, Cox C, Phelps DL, Sinkin RA. Two doses of early intravenous dexamethasone for the prevention of bronchopulmonary dysplasia in babies with respiratory distress syndrome. Pediatric Research 1994;36(1 Pt 1):122‐8. [DOI: 10.1203/00006450-199407001-00022; PUBMED: 7936832] - DOI - PubMed
    1. Sinkin RA. Personal communication. email 2002.
Shinwell 1996 {published data only}
    1. Shinwell ES. Early dexamethasone therapy is associated with increased incidence of cerebral palsy. Hot Topics' 99 in Neonatology 1999:240‐54.
    1. Shinwell ES. Personal communication. email 2002.
    1. Shinwell ES, Karplus M, Reich D, Weintraub Z, Blazer S, Bader D, et al. Early postnatal dexamethasone treatment and incidence of cerebral palsy. Archives of Disease in Childhood. Fetal and Neonatal Edition 2000;83(3):F177‐81. [PUBMED: 11040164] - PMC - PubMed
    1. Shinwell ES, Karplus M, Zmora E, Reich D, Rothschild A, Blazer S, et al. Failure of early postnatal dexamethasone to prevent chronic lung disease in infants with respiratory distress syndrome. Archives of Disease in Childhood. Fetal and Neonatal Edition 1996;74(1):F33‐7. [PUBMED: 8653433] - PMC - PubMed
Sinkin 2000 {published data only}
    1. D'Angio CT, Maniscalco WM, Ryan RM, Avissar NE, Basavegowda K, Sinkin RA. Vascular endothelial growth factor in pulmonary lavage fluid from premature infants: effects of age and postnatal dexamethasone. Biology of the Neonate 1999;76(5):266‐73. [DOI: ; PUBMED: 10516393] - PubMed
    1. Sinkin RA. Personal communication. email 2002.
    1. Sinkin RA, Dweck HS, Horgan MJ, Gallaher KJ, Cox C, Maniscalco WM, et al. Early dexamethasone ‐ attempting to prevent chronic lung disease. Pediatrics 2000;105(3 Pt 1):542‐8. [PUBMED: 10699107] - PubMed
Soll 1999 {published data only}
    1. Soll RF, Vermont Oxford Network Steroid Study Group. Early postnatal dexamethasone therapy for the prevention of chronic lung disease. Pediatric Research 1999;45:226A. - PubMed
    1. Vermont Oxford Network Steroid Study Group. Early postnatal dexamethasone therapy for the prevention of chronic lung disease. Pediatrics 2001;108(3):741‐8. [PUBMED: 11533345] - PubMed
Stark 2001 {published data only}
    1. Stark AR, Carlo WA, Tyson JE, Papile LA, Wright LL, Shankaran S, et al. National Institute of Child Health and Human Development Neonatal Research Network. Adverse effects of early dexamethasone in extremely‐low‐birth‐weight infants. New England Journal of Medicine 2001;344(2):95‐101. [DOI: 10.1056/NEJM200101113440203; PUBMED: 11150359] - DOI - PubMed
    1. Stark AR, Carlo WA, Vohr BR, Papile L, Saha S, Bauer CR, et al. Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network. Death or neurodevelopmental impairment at 18 to 22 months corrected age in a randomized trial of early dexamethasone to prevent death or chronic lung disease in extremely low birth weight infants. Journal of Pediatrics 2014; Vol. 164, issue 1:34‐9 e2. [DOI: 10.1016/j.jpeds.2013.07.027; PUBMED: 23992673] - DOI - PMC - PubMed
Subhedar 1997 {published data only}
    1. Subhedar NV. Personal communication. email 2002.
    1. Subhedar NV, Bennett AJ, Wardle SP, Shaw NJ. More trials on early treatment with corticosteroids are needed. BMJ 2000;320(7239):941. [PUBMED: 10742018 ] - PMC - PubMed
    1. Subhedar NV, Ryan SW, Shaw NJ. Open randomised controlled trial of inhaled nitric oxide and early dexamethasone in high risk preterm infants. Archives of Disease in Childhood. Fetal and Neonatal Edition 1997;77(3):F185‐90. [PUBMED: 9462187] - PMC - PubMed
Suske 1996 {published data only}
    1. Suske G, Oestreich K, Varnholt V, Lasch P, Kachel W. Influence of early postnatal dexamethasone therapy on ventilator dependency in surfactant‐substituted preterm infants. Acta Paediatrica 1996;85(6):713‐8. [PUBMED: 8816210] - PubMed
Tapia 1998 {published data only}
    1. Tapia JL, Ramirez R, Cifuentes J, Fabres J, Hubner ME, Bancalari A, et al. The effect of early dexamethasone administration on bronchopulmonary dysplasia in preterm infants with respiratory distress syndrome. Journal of Pediatrics 1998;132(1):48‐52. [PUBMED: 9469999] - PubMed
Vento 2004 {published data only}
    1. Vento G, Matassa PG, Zecca E, Tortorolo L, Martelli M, Carolis MP, et al. Effect of dexamethasone on tracheobronchial aspirate fluid cytology and pulmonary mechanics in preterm infants. Pharmacology 2004;71(3):113‐9. [DOI: 10.1159/000077444; PUBMED: 15161992] - DOI - PubMed
Wang 1996 {published data only}
    1. Wang JY, Yeh TF, Lin YC, Miyamura K, Holmskov U, Reid KB. Measurement of pulmonary status and surfactant protein levels during dexamethasone treatment of neonatal respiratory distress syndrome. Thorax 1996;51(9):907‐13. [PUBMED: 8984701] - PMC - PubMed
    1. Wang JY, Yeh TF, Lin YJ, Chen WY, Lin CH. Early postnatal dexamethasone therapy may lessen lung inflammation in premature infants with respiratory distress syndrome on mechanical ventilation. Pediatric Pulmonology 1997;23(3):193‐7. [PUBMED: 9094727] - PubMed
Watterberg 1999 {published data only}
    1. Watterberg KL. Personal communication. email 2002.
    1. Watterberg KL, Gerdes JS, Gifford KL, Lin HM. Prophylaxis against early adrenal insufficiency to prevent chronic lung disease in premature infants. Pediatrics 1999;104(6):1258‐63. [PUBMED: 10585975] - PubMed
Watterberg 2004 {published data only}
    1. Watterberg KL, Gerdes JS, Cole CH, Aucott SW, Thilo EH, Mammel MC, et al. Prophylaxis of early adrenal insufficiency to prevent bronchopulmonary dysplasia: a multicenter trial. Pediatrics 2004;114(6):1649‐57. [DOI: 10.1542/peds.2004-1159; PUBMED: 15574629] - DOI - PubMed
    1. Watterberg KL, Shaffer ML, Mishefske MJ, Leach CL, Mammel MC, Couser RJ, et al. Growth and neurodevelopmental outcomes after early low‐dose hydrocortisone treatment in extremely low birth weight infants. Pediatrics 2007;120(1):40‐8. [DOI: 10.1542/peds.2006-3158; PUBMED: 17606560] - DOI - PubMed
Yeh 1990 {published data only}
    1. Yeh TF, Torre JA, Rastogi A, Anyebuno MA, Pildes RS. Early postnatal dexamethasone therapy in premature infants with severe respiratory distress syndrome: a double‐blind, controlled study. Journal of Pediatrics 1990;117(2 Pt 1):273‐82. [PUBMED: 2199642] - PubMed
Yeh 1997 {published data only}
    1. Lin YJ, Lin CH, Wu JM, Tsai WH, Yeh TF. The effects of early postnatal dexamethasone therapy on pulmonary outcome in premature infants with respiratory distress syndrome: a two‐year follow‐up study. Acta Paediatrica 2005;94(3):310‐6. [PUBMED: 16028649] - PubMed
    1. Lin YJ, Yeh TF, Lin HC, Wu JM, Lin CH, Yu CY. Effects of early postnatal dexamethasone therapy on calcium homeostasis and bone growth in preterm infants with respiratory distress syndrome. Acta Paediatrica 1998;87(10):1061‐5. [PUBMED: 9825973] - PubMed
    1. Peng CT, Lin HC, Lin YJ, Tsai CH, Yeh TF. Early dexamethasone therapy and blood cell count in preterm infants. Pediatrics 1999;104(3 Pt 1):476‐81. [PUBMED: 10469772] - PubMed
    1. Yeh TF, Lin I, Shieh W, Lin H, Chen J, Kao S. Prevention of chronic lung disease (CLD) in premature RDS infants with early and prolonged dexamethasone (D) therapy ‐ a multicenter double‐blind controlled study. Pediatric Research 1994;35(4):262A.
    1. Yeh TF, Lin YJ, Hsieh WS, Lin HC, Lin CH, Chen JY, et al. Early postnatal dexamethasone therapy for the prevention of chronic lung disease in preterm infants with respiratory distress syndrome: a multicenter clinical trial. Pediatrics 1997;100(4):E3. [PUBMED: 9310536] - PubMed

References to studies excluded from this review

Ariagno 1987 {unpublished data only}
    1. Ariagno RL, Sweeney TE, Baldwin RB, Inguillo D, Martin D. Controlled trial of dexamethasone in preterm infants at risk for bronchopulmonary dysplasia: lung function, clinical course and outcome at three years (as supplied 2000). Data on file.
    1. Ariagno RL, Sweeney TJ, Baldwin RB, Inguillo D, Martin D. Dexamethasone effects on lung function and risks in 3 week old ventilatory dependent preterm infants. American Reviews of Respiratory Disease 1987;135:A125.
Avery 1985 {published data only}
    1. Avery GB, Fletcher AB, Kaplan M, Brudno DS. Controlled trial of dexamethasone in respirator‐dependent infants with bronchopulmonary dysplasia. Pediatrics 1985;75(1):106‐11. [PUBMED: 3880879] - PubMed
Brozanski 1995 {published data only}
    1. Brozanski BS, Jones JG, Gilmour CH, Balsan MJ, Vazquez RL, Israel BA, et al. Effect of pulse dexamethasone therapy on the incidence and severity of chronic lung disease in the very low birth weight infant. Journal of Pediatrics 1995;126(5 Pt 1):769‐76. [PUBMED: 7752005] - PubMed
    1. Gilmour CH, Sentipal‐Walerius JM, Jones JG, Doyle JM, Brozanski BS, Balsan MJ, et al. Pulse dexamethasone does not impair growth and body composition of very low birth weight infants. Journal of the American College of Nutrition 1995;14(5):455‐62. [PUBMED: 8522724] - PubMed
    1. Hofkosh D, Brozanski BS, Edwards DE, Williams LA, Jones JG, Cheng KP. One year outcome of infants treated with pulse dexamethasone for prevention of BPD. Pediatric Research 1995;37(4):259A.
CDTG 1991 {published data only}
    1. Collaborative Dexamethasone Trial Group. Dexamethasone therapy in neonatal chronic lung disease: an international placebo‐controlled trial. Pediatrics 1991;88(3):421‐7. [PUBMED: 1881718] - PubMed
    1. Jones R, Wincott E, Elbourne D, Grant A. Controlled trial of dexamethasone in neonatal chronic lung disease: a 3‐year follow‐up. Pediatrics 1995;96(5 Pt 1):897‐906. [PUBMED: 7478833] - PubMed
    1. Jones RA, Collaborative Dexamethasone Trial Follow‐up Group. Randomized, controlled trial of dexamethasone in neonatal chronic lung disease: 13‐ to 17‐year follow‐up study: I. Neurologic, psychological, and educational outcomes. Pediatrics 1995;116(2):370‐8. [DOI: 10.1542/peds.2004-1818; PUBMED: 16061591] - DOI - PubMed
    1. Jones RA, Collaborative Dexamethasone Trial Follow‐up Group. Randomized, controlled trial of dexamethasone in neonatal chronic lung disease: 13‐ to 17‐year follow‐up study: II. Respiratory status, growth, and blood pressure. Pediatrics 2005;116(2):379‐84. [DOI: 10.1542/peds.2004-1819; PUBMED: 16061592] - DOI - PubMed
Cummings 1989 {published data only}
    1. Cummings JJ. Personal communication. email 2002.
    1. Cummings JJ, D'Eugenio DB, Gross SJ. A controlled trial of dexamethasone in preterm infants at high risk for bronchopulmonary dysplasia. New England Journal of Medicine 1989;320(23):1505‐10. [DOI: 10.1056/NEJM198906083202301; PUBMED: 2657423] - DOI - PubMed
    1. Gross SJ, Anbar RD, Mettelman BB. Follow‐up at 15 years of preterm infants from a controlled trial of moderately early dexamethasone for the prevention of chronic lung disease. Pediatrics 2005;115(3):681‐7. [DOI: 10.1542/peds.2004-0956; PUBMED: 15741372] - DOI - PubMed
Dobryansky 2012 {published data only}
    1. Dobryansky D, Borysiuk O, Salabay Z, Dubrovna Y. Clinical effectiveness of early administration of caffeine and low‐dose hydrocortisone to preterm newborns with a high risk of BPD development. Archives of Disease in Childhood 2012;97:A119. [DOI: 10.1136/archdischild-2012-302724.0405] - DOI
Doyle 2006 {published data only}
    1. Doyle LW, Davis PG, Morley CJ, McPhee A, Carlin JB. Low‐dose dexamethasone facilitates extubation among chronically ventilator‐dependent infants: a multicenter, international, randomized, controlled trial. Pediatrics 2006;117(1):75‐83. [PUBMED: 16396863] - PubMed
    1. Doyle LW, Davis PG, Morley CJ, McPhee A, Carlin JB, DART Study Investigators. Outcome at 2 years of age of infants from the DART study: a multicenter, international, randomized, controlled trial of low‐dose dexamethasone. Pediatrics 2007;119(4):716‐21. [DOI: 10.1542/peds.2006-2806; PUBMED: 17403842 ] - DOI - PubMed
Durand 1995 {published data only}
    1. Durand M, Sardesai S, McEvoy C. Effects of early dexamethasone therapy on pulmonary mechanics and chronic lung disease in very low birth weight infants: a randomized, controlled trial. Pediatrics 1995;95(4):584‐90. [PUBMED: 7700763] - PubMed
Gaissmaier 1999 {published data only}
    1. Gaissmaier RE, Pohlandt F. Single‐dose dexamethasone treatment of hypotension in preterm infants. Journal of Pediatrics 1999;134(6):701‐5. [PUBMED: 10356137] - PubMed
Gross 2005 {published data only}
    1. Gross SJ, Anbar RD, Mettelman BB. Follow‐up at 15 years of preterm infants from a controlled trial of moderately early dexamethasone for the prevention of chronic lung disease. Pediatrics 2005;115(3):681‐7. [10.1542/peds.2004‐0956; PUBMED: 15741372] - PubMed
Harkavy 1989 {published data only}
    1. Harkavy KL, Scanlon JW, Chowdhry PK, Grylack LJ. Dexamethasone therapy for chronic lung disease in ventilator‐ and oxygen‐dependent infants: a controlled trial. Journal of Pediatrics 1989;115(6):979‐83. [PUBMED: 2685220] - PubMed
Kari 1993 {published data only}
    1. Kari MA, Heinonen K, Ikonen RS, Koivisto M, Raivio KO. Dexamethasone treatment in preterm infants at risk for bronchopulmonary dysplasia. Archives of Disease in Childhood 1993;68(5 Spec No):566‐9. [PUBMED: 8323356] - PMC - PubMed
    1. Kari MA, Raivio KO, Venge P, Hallman M. Dexamethasone treatment of infants at risk for chronic lung disease: surfactant components and inflammatory parameters in airway specimens. Pediatric Research 1994;36(3):387‐93. [DOI: 10.1203/00006450-199409000-00020; PUBMED: 7808837] - DOI - PubMed
    1. Mieskonen S, Eronen M, Malmberg LP, Turpeinen M, Kari MA, Hallman M. Controlled trial of dexamethasone in neonatal chronic lung disease: an 8‐year follow‐up of cardiopulmonary function and growth. Acta Paediatrica 2003;92(8):896‐904. [PUBMED: 12948063] - PubMed
Kazzi 1990 {published data only}
    1. Kazzi NJ, Brans YW, Poland RL. Dexamethasone effects on the hospital course of infants with bronchopulmonary dysplasia who are dependent on artificial ventilation. Pediatrics 1990;86(5):722‐7. [PUBMED: 2235226] - PubMed
Kothadia 1999 {published data only}
    1. Bensky AS, Kothadia JM, Covitz W. Cardiac effects of dexamethasone in very low birth weight infants. Pediatrics 1996;97(6 Pt 1):818‐21. [PUBMED: 8657520] - PubMed
    1. Goldstein DJ, Waldrep EL, VanPelt JC, O'Shea TM. Developmental outcome at 5 years following dexamethasone use for very low birth weight infants. Pediatric Research 2000;47(4):310A.
    1. Kothadia JM, O'Shea TM, Roberts D, Auringer ST, Weaver RG 3rd, Dillard RG. Randomized placebo‐controlled trial of a 42‐day tapering course of dexamethasone to reduce the duration of ventilator dependency in very low birth weight infants. Pediatrics 1999;104(1 Pt 1):22‐7 Erratum in: Pediatrics 2004; 114(6):1746. [PUBMED: 10390255] - PubMed
    1. Nixon PA, Washburn LK, Schechter MS, O'Shea TM. Follow‐up study of a randomized controlled trial of postnatal dexamethasone therapy in very low birth weight infants: effects on pulmonary outcomes at age 8 to 11 years. Journal of Pediatrics 2007;150(4):345‐50. [DOI: 10.1016/j.jpeds.2006.12.013; PUBMED: 17382108] - DOI - PMC - PubMed
    1. O'Shea TM, Goldstein DJ, Jackson BG, Kothadia JM, Dillard RG. Randomized trial of a 42‐day tapering course of dexamethasone in very low birth weight infants: neurological, medical and functional outcome at 5 years of age. Pediatric Research 2000;47(4):319A.
Kovacs 1998 {published data only}
    1. Kovacs L, Davis GM, Faucher D, Papageorgiou A. Efficacy of sequential early systemic and inhaled corticosteroid therapy in the prevention of chronic lung disease of prematurity. Acta Paediatrica 1998;87(7):792‐8. [PUBMED: 9722255] - PubMed
Noble‐Jamieson 1989 {published data only}
    1. Noble‐Jamieson CM, Regev R, Silverman M. Dexamethasone in neonatal chronic lung disease: pulmonary effects and intracranial complications. European Journal of Pediatrics 1989;148(4):365‐7. [PUBMED: 2651132] - PubMed
Ohlsson 1992 {published data only}
    1. Ohlsson A, Calvert SA, Hosking M, Shennan AT. Randomized controlled trial of dexamethasone treatment in very‐low‐birth‐weight infants with ventilator‐dependent chronic lung disease. Acta Paediatrica 1992;81(10):751‐6. [PUBMED: 1421877] - PubMed
Papile 1998 {published data only}
    1. Papile LA, Tyson JE, Stoll BJ, Wright LL, Donovan EF, Bauer CR, et al. A multicenter trial of two dexamethasone regimens in ventilator‐dependent premature infants. New England Journal of Medicine 1998;338(16):1112‐8. [DOI: 10.1056/NEJM199804163381604; PUBMED: 9545359] - DOI - PubMed
    1. Stoll BJ, Temprosa M, Tyson JE, Papile LA, Wright LL, Bauer CR, et al. Dexamethasone therapy increases infection in very low birth weight infants. Pediatrics 1999;104(5):e63. [PUBMED: 10545589] - PubMed
Parikh 2013 {published data only}
    1. Parikh NA, Kennedy KA, Lasky RE, McDavid GE, Tyson JE. Pilot randomized trial of hydrocortisone in ventilator‐dependent extremely preterm infants: effects on regional brain volumes. Journal of Pediatrics 2013;162(4):685‐90. [DOI: 10.1016/j.jpeds.2012.09.054; PUBMED: 23140612] - DOI - PMC - PubMed
Romagnoli 1997 {published data only}
    1. Romagnoli C, Vento G, Zecca E, Tortorolo G, Papacci P, Carolis M, et al. Dexamethasone for the prevention of chronic lung disease in preterm neonates: a prospective randomized study [II desametazone nella prevenzione della patologia polmonare cronica del neonato pretermine: studio prospettico randomizzato]. Rivista Italiana di Pediatria [Italian Journal of Pediatrics] 1997;24:283‐8.
    1. Romagnoli C, Zecca E, Luciano R, Torrioli G, Tortorolo G. A three year follow up of preterm infants after moderately early treatment with dexamethasone. Archives of Disease in Childhood. Fetal and Neonatal Edition 2002;87(1):F55‐8. [12091294] - PMC - PubMed
    1. Romagnoli C, Zecca E, Vento G, Maggio L, Papacci P, Tortorolo G. Effect on growth of two different dexamethasone courses for preterm infants at risk of chronic lung disease. A randomized trial. Pharmacology 1999;59(5):266‐74. [PUBMED: 10529659] - PubMed
Salas 2014 {published data only}
    1. Salas G, Travaglianti M, Leone A, Couceiro C, Rodríguez S, Fariña D. Hydrocortisone for the treatment of refractory hypotension:a randomised controlled trial [Hidrocortisona para el tratamiento de hipotensión refractaria: ensayo clínico controlado y aleatorizado]. Anales de Pediatria (Barcelona, Spain : 2003) 2014;80(6):387‐93. [DOI: 10.1016/j.anpedi.2013.08.004; PUBMED: 24139558] - DOI - PubMed
Scott 1997 {published data only}
    1. Scott SM, Backstrom C, Bessman S. Effect of five days of dexamethasone therapy on ventilator dependence and adrenocorticotropic hormone‐stimulated cortisol concentrations. Journal of Perinatology 1997;17(1):24‐8. [PUBMED: 9069060] - PubMed
Smolkin 2014 {published data only}
    1. Smolkin T, Ulanovsky I, Jubran H, Blazer S, Makhoul IR. Experience with oral betamethasone in extremely low birthweight infants with bronchopulmonary dysplasia. Archives of Disease in Childhood. Fetal and Neonatal Edition 2014;99(6):F517‐8. [DOI: 10.1136/archdischild-2014-306619; PUBMED: 25074982] - DOI - PubMed
Tsukahara 1999 {published data only}
    1. Tsukahara H, Watanabe Y, Yasutomi M, Kobata R, Tamura S, Kimura K, et al. Early (4‐7 days of age) dexamethasone therapy for prevention of chronic lung disease in preterm infants. Biology of the Neonate 1999;76(5):283‐90. [DOI: ; PUBMED: 10516395] - PubMed
Vincer 1998 {published data only}
    1. Vincer MJ, Allen AC. Double blind randomized controlled trial of 6‐day pulse of dexamethasone for very low birth weight infants (VLBW <1500 grams) who are ventilator dependent at 4 weeks of age. Pediatric Research 1998;43:201A.
Walther 2003 {published data only}
    1. Walther FJ, Findlay RD, Durand M. Adrenal suppression and extubation rate after moderately early low‐dose dexamethasone therapy in very preterm infants. Early Human Development 2003;74(1):37‐45. [PUBMED: 14512180] - PubMed
Yaseen 1999 {published data only}
    1. Yaseen H, Okash I, Hanif M, al‐Umran K, al‐Faraidy A. Early dexamethasone treatment in preterm infants treated with surfactant: a double blind controlled trial. Journal of Tropical Pediatrics 1999;45(5):304‐6. [DOI: ] - PubMed

Additional references

Anonymous 1991
    1. [No authors listed]. Dexamethasone for neonatal chronic lung disease. Lancet 1991;338(8773):982‐3. [PUBMED: 1681347] - PubMed
Arias‐Camison 1999
    1. Arias‐Camison JM, Lau J, Cole CH, Frantz ID 3rd. Meta‐analysis of dexamethasone therapy started in the first 15 days of life for prevention of chronic lung disease in premature infants. Pediatric Pulmonology 1999;28(3):167‐74. [PUBMED: 10495332] - PubMed
Baud 1999
    1. Baud O, Foix‐L'Helias L, Kaminski M, Audibert F, Jarreau PH, Papiernik E, et al. Antenatal glucocorticoid treatment and cystic periventricular leukomalacia in very preterm infants. New England Journal of Medicine 1999;341(16):1190‐6. [DOI: 10.1056/NEJM199910143411604; PUBMED: 10519896] - DOI - PubMed
Bayley 1993
    1. Bayley, N. Bayley Scales of Infant Development. 2nd Edition. San Antonio: The Psychological Corporation, 1993.
Bhuta 1998
    1. Bhuta T, Ohlsson A. Systematic review and meta‐analysis of early postnatal dexamethasone for prevention of chronic lung disease. Archives of Disease in Childhood. Fetal and Neonatal Edition 1998;79(1):F26‐33. [PUBMED: 9797621] - PMC - PubMed
Doyle 2000
    1. Doyle LW, Davis PG. Postnatal corticosteroids in preterm infants: systematic review of effects on mortality and motor function. Journal of Paediatrics and Child Health 2000;36(2):101‐7. [PUBMED: 10760004] - PubMed
Doyle 2010a
    1. Doyle LW, Ehrenkranz RA, Halliday HL. Postnatal hydrocortisone for preventing or treating bronchopulmonary dysplasia in preterm infants: a systematic review. Neonatology 2010;98(2):111‐7. [DOI: 10.1159/000279992; PUBMED: 20150750] - DOI - PubMed
Doyle 2010b
    1. Doyle LW, Ehrenkranz RA, Halliday HL. Dexamethasone treatment in the first week of life for preventing bronchopulmonary dysplasia in preterm infants: a systematic review. Neonatology 2010;98(3):217‐24. [DOI: 10.1159/000286210; PUBMED: 20389126] - DOI - PubMed
Doyle 2010c
    1. Doyle LW, Ehrenkranz RA, Halliday HL. Dexamethasone treatment after the first week of life for bronchopulmonary dysplasia in preterm infants: a systematic review. Neonatology 2010;98(4):289‐96. [DOI: 10.1159/000286212; PUBMED: 20453523] - DOI - PubMed
Doyle 2014b
    1. Doyle LW, Ehrenkranz RA, Halliday HL. Late (> 7 days) postnatal corticosteroids for chronic lung disease in preterm infants. Cochrane Database of Systematic Reviews 2014, Issue 5. [DOI: 10.1002/14651858.CD001145.pub3] - DOI - PubMed
Doyle 2017
    1. Doyle LW, Cheong J, Ehrenkranz RA, Halliday HL. Late (> 7 days) systemic postnatal corticosteroids for prevention of bronchopulmonary dysplasia in preterm infants. Cochrane Database of Systematic Reviews 2017, Issue 10. [DOI: 10.1002/14651858.CD001145.pub4] - DOI - PMC - PubMed
Egberts 1997
    1. Egberts J, Brand R, Walti H, Bevilacqua G, Breart G, Gardini F. Mortality, severe respiratory distress syndrome and chronic lung disease of the newborn are reduced more after prophylactic than after therapeutic administration of the surfactant Curosurf. Pediatrics 1997;100(1):E4. [PUBMED: 9200378] - PubMed
Fitzhardinge 1974
    1. Fitzhardinge PM, Eisen A, Lejtenyi C, Metrakos K, Ramsay M. Sequelae of early steroid administration to the newborn infant. Pediatrics 1974;53(6):877‐83. [PUBMED: 4598934] - PubMed
Gibson 1993
    1. Gibson AT, Pearse RG, Wales JKH. Growth retardation after dexamethasone administration: assessment by knemometry. Archives of Disease in Childhood 1993;69(5 Spec No):505‐9. [PUBMED: 8285754] - PMC - PubMed
GRADEpro GDT [Computer program]
    1. GRADE Working Group, McMaster University (developed by Evidence Prime). GRADEpro GDT. Version accessed 21 February 2017. Hamilton (ON): GRADE Working Group, McMaster University (developed by Evidence Prime), 2015. Available from gradepro.org.
Gramsbergen 1998
    1. Gramsbergen A, Mulder EJH. The influence of betamethasone and dexamethasone on motor development in young rats. Pediatric Research 1998;44(1):105‐10. [DOI: 10.1203/00006450-199807000-00017; PUBMED: 9667379] - DOI - PubMed
Groneck 1995
    1. Groneck P, Speer CP. Inflammatory mediators and bronchopulmonary dysplasia. Archives of Disease in Childhood. Fetal and Neonatal Edition 1995;73(1):F1‐3. [PUBMED: 7552588] - PMC - PubMed
Halliday 1997
    1. Halliday HL. A review of postnatal corticosteroids for treatment and prevention of chronic lung disease in the preterm infant. Prenatal and Neonatal Medicine 1997;2:1‐12.
Halliday 1999
    1. Halliday HL. Clinical trials of postnatal corticosteroids: inhaled and systemic. Biology of the Neonate 1999;76(Suppl 1):29‐40. [PUBMED: 10393391] - PubMed
Higgins 2011
    1. Higgins JP, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
Mammel 1983
    1. Mammel MC, Green TP, Johnson DE, Thompson TR. Controlled trial of dexamethasone therapy in infants with bronchopulmonary dysplasia. Lancet 1983;1(8338):1356‐8. [PUBMED: 6134136] - PubMed
Ng 1993
    1. Ng PC. The effectiveness and side effects of dexamethasone in preterm infants with bronchopulmonary dysplasia. Archives of Disease in Childhood 1993;68(3 Spec No):330‐6. [PUBMED: 8466274] - PMC - PubMed
Onland 2017
    1. Onland W, Offringa M, Kaam A. Late (≥ 7 days) inhalation corticosteroids to reduce bronchopulmonary dysplasia in preterm infants. Cochrane Database of Systematic Reviews 2017, Issue 8. [DOI: 10.1002/14651858.CD002311.pub4] - DOI - PMC - PubMed
Papile 1996
    1. Papile LA, Stoll B, Donovan E, Tyson I, Bauer C, Wright L, et al. Dexamethasone therapy in infants at risk for chronic lung disease (CLD): a multicenter, randomized, double‐masked trial. Pediatric Research 1996;39:236A.
Peltoniemi 2009
    1. Peltoniemi OM, Lano A, Puosi R, Yliherva A, Bonsante F, Kari M A, et al. Neonatal Hydrocortisone Working Group. Trial of early neonatal hydrocortisone: two‐year follow‐up. Neonatology 2009;95(3):240‐7. [DOI: 10.1159/000164150; PUBMED: 18931525] - DOI - PubMed
Peltoniemi 2016
    1. Peltoniemi OM, Lano A, Yliherva A, Kari M A, Hallman M, Neonatal Hydrocortisone Working Group. Randomised trial of early neonatal hydrocortisone demonstrates potential undesired effects on neurodevelopment at preschool age. Acta Paediatrica 2016;105(2):159‐64. [DOI: 10.1111/apa.13074; PUBMED: 26058477] - DOI - PubMed
RevMan 2014 [Computer program]
    1. Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
Romagnoli 2002
    1. Romagnoli C, Zecca E, Luciano R, Torrioli G, Tortorolo G. Controlled trial of early dexamethasone treatment for the prevention of chronic lung disease in preterm infants: a 3‐year follow‐up. Pediatrics 2002;109(6):e85. [PUBMED: 12042579] - PubMed
Ryan 1996
    1. Ryan SW, Nycyk J, Shaw NJ. Prediction of chronic neonatal lung disease on day 4 of life. European Journal of Pediatrics 1996;155(8):668‐71. [PUBMED: 8839722] - PubMed
Schmidt 2006
    1. Schmidt B, Roberts RS, Davis P, Doyle LW, Barrington KJ, Ohlsson A, et al. Caffeine for Apnea of Prematurity Trial Group. Caffeine therapy for apnea of prematurity. New England Journal of Medicine 2006;354(20):2112‐21. - PubMed
Schünemann 2013
    1. Schünemann H, Brożek J, Guyatt G, Oxman A, editors. GRADE Working Group. GRADE Handbook for Grading Quality of Evidence and Strength of Recommendations. Available from https://gdt.gradepro.org/app/handbook/handbook.html. Updated October 2013.
Shah 2007b
    1. Shah V, Ohlsson A, Halliday H, Dunn MS. Early administration of inhaled corticosteroids for preventing chronic lung disease in ventilated very low birth weight preterm neonates. Cochrane Database of Systematic Reviews 2007, Issue 4. [DOI: 10.1002/14651858.CD001969.pub2] - DOI - PubMed
Shah 2012a
    1. Shah SS, Ohlsson A, Halliday HL, Shah VS. Inhaled versus systemic corticosteroids for preventing chronic lung disease in ventilated very low birth weight preterm neonates. Cochrane Database of Systematic Reviews 2012, Issue 5. [DOI: 10.1002/14651858.CD002058.pub2] - DOI - PubMed
Shah 2012b
    1. Shah SS, Ohlsson A, Halliday HL, Shah VS. Inhaled versus systemic corticosteroids for the treatment of chronic lung disease in ventilated very low birth weight preterm infants. Cochrane Database of Systematic Reviews 2012, Issue 5. [DOI: 10.1002/14651858.CD002057.pub3] - DOI - PubMed
Shah 2017
    1. Shahh VS, Ohlsson A, Halliday HL, Dunn M. Early administration of inhaled corticosteroids for preventing chronic lung disease in very low birth weight preterm neonates. Cochrane Database of Systematic Reviews 2017, Issue 1. [DOI: 10.1002/14651858.CD001969.pub4] - DOI - PMC - PubMed
Shinwell 2002
    1. Shinwell ES, Karplus M, Reich D, Weintraub Z, Blazer S, Bader D, et al. Early postnatal dexamethasone treatment and increased incidence of cerebral palsy. Archives of Disease in Childhood. Fetal and Neonatal Edition 2000;83(3):F177‐81. [PUBMED: 11040164] - PMC - PubMed
Stanley 1982
    1. Stanley FJ. Using cerebral palsy data in the evaluation of neonatal intensive care: a warning. Developmental Medicine and Child Neurology 1982;24(1):93‐4. [PUBMED: 7106413] - PubMed
Stark 2014
    1. Stark AR, Carlo WA, Vohr BR, Papile LA, Saha S, Bauer CR, et al. Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network. Death or neurodevelopmental impairment at 18 to 22 months corrected age in a randomized trial of early dexamethasone to prevent death or chronic lung disease in extremely low birth weight infants. Journal of Pediatrics 2014;164(1):34‐9 e2. [DOI: 10.1016/j.jpeds.2013.07.027; PUBMED: 23992673] - DOI - PMC - PubMed
Tarnow‐Mordi 1999
    1. Tarnow‐Mordi W, Mitra A. Postnatal dexamethasone in preterm infants is potentially life saving, but follow up studies are urgently needed. BMJ 1999;319(7222):1385‐6. [PUBMED: 10574836] - PMC - PubMed
Tschanz 1995
    1. Tschanz SA, Damke BM, Burri PH. Influence of postnatally administered glucocorticoids on rat lung growth. Biology of the Neonate 1995;68(4):229‐45. [PUBMED: 8580214] - PubMed
van Goudoever 1994
    1. Goudoever JB, Wattimena JD, Carnielli VP, Sulkers EJ, Degenhart HJ, Sauer PJ. Effect of dexamethasone on protein metabolism in infants with bronchopulmonary dysplasia. Journal of Pediatrics 1994;124(1):112‐8. [PUBMED: 8283359] - PubMed
Watterberg 2007
    1. Watterberg KL, Shaffer ML, Mishefske MJ, Leach CL, Mammel MC, Couser RJ, et al. Growth and developmental outcomes after early low‐dose hydrocortisone treatment in extremely low birth weight infants. Pediatrics 2007;120(1):40‐8. [DOI: 10.1542/peds.2006-3158; PUBMED: 17606560] - DOI - PubMed
Weichsel 1977
    1. Weichsel ME. The therapeutic use of glucocorticoid hormones in the perinatal period: potential neurologic hazards. Annals of Neurology 1977;2(5):364‐6. [DOI: 10.1002/ana.410020503; PUBMED: 617574] - DOI - PubMed
Werner 1992
    1. Werner JC, Sicard RE, Hansen TWR, Solomon E, Cowett RM, Oh W. Hypertrophic cardiomyopathy associated with dexamethasone therapy for bronchopulmonary dysplasia. Journal of Pediatrics 1992;120(2 Pt 1):286‐91. [PUBMED: 1735831] - PubMed
Yeh 1998
    1. Yeh TF, Lin YJ, Huang CC, Chen YJ, Lin CH, Lin HC, et al. Early dexamethasone therapy in preterm infants: a follow up study. Pediatrics 1998;101(5):E7. [PUBMED: 9565440] - PubMed
Yeh 2004
    1. Yeh TF, Lin YJ, Lin HC, Huang CC, Hsieh WS, Lin CH, et al. Outcomes at school age after postnatal dexamethasone therapy for lung disease of prematurity. New England Journal of Medicine 2004;350(13):1304‐13. [DOI: 10.1056/NEJMoa032089; PUBMED: 15044641] - DOI - PubMed

References to other published versions of this review

Doyle 2014a
    1. Doyle LW, Ehrenkranz RA, Halliday HL. Early (< 8 days) postnatal corticosteroids for preventing chronic lung disease in preterm infants. Cochrane Database of Systematic Reviews 2014, Issue 5. [DOI: 10.1002/14651858.CD001146.pub4] - DOI - PubMed
Halliday 2000
    1. Halliday HL, Ehrenkranz RA. Early postnatal (< 96 hours) corticosteroids for preventing chronic lung disease in preterm infants. Cochrane Database of Systematic Reviews 2000, Issue 2. [DOI: 10.1002/14651858.CD001146] - DOI - PubMed
Halliday 2001
    1. Halliday HL, Ehrenkranz RA. Early postnatal (< 96 hours) corticosteroids for preventing chronic lung disease in preterm infants. Cochrane Database of Systematic Reviews 2001, Issue 1. [DOI: 10.1002/14651858.CD001146] - DOI - PubMed
Halliday 2003b
    1. Halliday HL, Ehrenkranz RA, Doyle LW. Early (< 96 hours) postnatal corticosteroids for preventing chronic lung disease in preterm infants. Cochrane Database of Systematic Reviews 2003, Issue 1. [DOI: 10.1002/14651858.CD001146] - DOI - PubMed
Halliday 2010
    1. Halliday HL, Ehrenkranz RA, Doyle LW. Early (< 8 days) postnatal corticosteroids for preventing chronic lung disease in preterm infants. Cochrane Database of Systematic Reviews 2010, Issue 1. [DOI: 10.1002/14651858.CD001146.pub3] - DOI - PubMed

Publication types

MeSH terms